207 related articles for article (PubMed ID: 18560614)
1. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
2. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
3. Beyond a decade of 5% imiquimod topical therapy.
A Gaspari A; Tyring SK; Rosen T
J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
[TBL] [Abstract][Full Text] [Related]
4. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
5. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
6. TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study.
Piaserico S; Michelotto A; Frigo AC; Alaibac M
Pharmacogenomics; 2015 Nov; 16(17):1913-7. PubMed ID: 26556041
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
[TBL] [Abstract][Full Text] [Related]
8. The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
Miller RL; Meng TC; Tomai MA
Drug News Perspect; 2008 Mar; 21(2):69-87. PubMed ID: 18389099
[TBL] [Abstract][Full Text] [Related]
9. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
10. Modes of action of TLR7 agonists in cancer therapy.
Kobold S; Wiedemann G; Rothenfußer S; Endres S
Immunotherapy; 2014; 6(10):1085-95. PubMed ID: 25428647
[TBL] [Abstract][Full Text] [Related]
11. TLR7 and TLR8 as targets in cancer therapy.
Schön MP; Schön M
Oncogene; 2008 Jan; 27(2):190-9. PubMed ID: 18176600
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action and other potential roles of an immune response modifier.
Gaspari AA
Cutis; 2007 Apr; 79(4 Suppl):36-45. PubMed ID: 17508494
[TBL] [Abstract][Full Text] [Related]
13. Innovative uses of imiquimod.
Vender RB; Goldberg O
J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis.
Ahn MY; Kwon SM; Cheong HH; Park JH; Lee J; Min SK; Ahn SG; Yoon JH
J Oral Pathol Med; 2012 Aug; 41(7):540-6. PubMed ID: 22577802
[TBL] [Abstract][Full Text] [Related]
15. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.
Huen AO; Rook AH
Curr Opin Oncol; 2014 Mar; 26(2):237-44. PubMed ID: 24441505
[TBL] [Abstract][Full Text] [Related]
16. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.
Spaner DE; Miller RL; Mena J; Grossman L; Sorrenti V; Shi Y
Leuk Lymphoma; 2005 Jun; 46(6):935-9. PubMed ID: 16019542
[TBL] [Abstract][Full Text] [Related]
17. Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.
Fletcher S; Steffy K; Averett D
Curr Opin Investig Drugs; 2006 Aug; 7(8):702-8. PubMed ID: 16955681
[TBL] [Abstract][Full Text] [Related]
18. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.
Stary G; Bangert C; Tauber M; Strohal R; Kopp T; Stingl G
J Exp Med; 2007 Jun; 204(6):1441-51. PubMed ID: 17535975
[TBL] [Abstract][Full Text] [Related]
19. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
Schön MP; Schön M; Klotz KN
J Invest Dermatol; 2006 Jun; 126(6):1338-47. PubMed ID: 16575388
[TBL] [Abstract][Full Text] [Related]
20. The imidazoquinolines and their place in the therapy of cutaneous disease.
Smith KJ; Hamza S; Skelton H
Expert Opin Pharmacother; 2003 Jul; 4(7):1105-19. PubMed ID: 12831337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
